These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach? Mahendran S; Sethi T QJM; 2012 Oct; 105(10):929-34. PubMed ID: 22647761 [TBL] [Abstract][Full Text] [Related]
5. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Xaubet A; Serrano-Mollar A; Ancochea J Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635 [TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for idiopathic pulmonary fibrosis. Selman M; Pardo A; Richeldi L; Cerri S Expert Opin Emerg Drugs; 2011 Jun; 16(2):341-62. PubMed ID: 21410428 [TBL] [Abstract][Full Text] [Related]
7. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Hara A; Sakamoto N; Ishimatsu Y; Kakugawa T; Nakashima S; Hara S; Adachi M; Fujita H; Mukae H; Kohno S Respir Med; 2012 Apr; 106(4):571-80. PubMed ID: 22209187 [TBL] [Abstract][Full Text] [Related]
8. Existing and emerging treatments for idiopathic pulmonary fibrosis. Kolilekas L; Papiris S; Bouros D Expert Rev Respir Med; 2019 Mar; 13(3):229-239. PubMed ID: 30632421 [TBL] [Abstract][Full Text] [Related]
9. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis. Aryal S; Nathan SD Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Trachalaki A; Irfan M; Wells AU Expert Opin Pharmacother; 2021 Feb; 22(2):191-204. PubMed ID: 32993388 [TBL] [Abstract][Full Text] [Related]